Beam Therapeutics Inc. BEAM
26.37 USD +0.49 (+1.91%)
Nov 6, 2026, 11:16 AM EST
25.86 Day range 26.75
20.23 52-week range 38.26
- YTD
- -4.89%
- 1 year
- +13.89%
News
benzinga.com Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51 Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.
benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.
benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.
benzinga.com Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON…
globenewswire.com Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social…
zacks.com Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.
benzinga.com Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of…
globenewswire.com Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected…
zacks.com 3 Promising Genomics Stocks to Add to Your Portfolio Now Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
benzinga.com Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? Ondas, Dutch Bros and Under Armour are among the most-heavily shorted stocks in the market right now.
benzinga.com Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79 Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.- benzinga.com Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28 Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.
- benzinga.com Beam Therapeutics Announces Initial Data From Its Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia; In The 40 Mg Cohort, Two Patients Achieved 15 Hours Of Controlled Fasting; Safety Profile Of BEAM-301 Consistent With LNP-Based Therapies The data will be presented during a poster session at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany. BEAM-301 is an investigational…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
- benzinga.com Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
benzinga.com Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.- benzinga.com Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIaInitial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with…
benzinga.com Squeeze Watch: 10 Stocks With Over 33% Short Interest Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com These 10 Stocks Are Squeeze Candidates Waiting to Happen These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
benzinga.com Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
benzinga.com Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.- benzinga.com Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302Treatment with BEAM-302 Increased Total and Functional AAT…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
benzinga.com Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of…
benzinga.com Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026 Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the…
benzinga.com Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.- benzinga.com B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
benzinga.com Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED) Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.- benzinga.com The FDA Clears Beam Therapeutics' Investigational New Drug Application For BEAM-304 For Phenylketonuria Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration…
- benzinga.com Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FL BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy.…
- benzinga.com Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39 Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
benzinga.com Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas Inc's losses and praised companies like Halliburton and Nokia.
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
benzinga.com Earnings Scheduled For February 24, 2026 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday 
benzinga.com Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
benzinga.com WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday 
benzinga.com My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
benzinga.com Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
benzinga.com Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday 
benzinga.com Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.
benzinga.com Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - benzinga.com IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
- benzinga.com Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
- benzinga.com Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
benzinga.com Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers